The Interaction Between the Microbiome and Tumors

Zong, Yang; Zhou, Yujie; Liao, Binyou; Liao, Min; Shi, Yangyang; Yu, Wei; Huang, Yu‐Yao; Cheng, Lei; Ren, Baiping

doi:10.3389/fcimb.2021.673724

Cited by 16 publications

(11 citation statements)

References 140 publications

(231 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a strong correlation between the microbiome and tumor development, however, the causation and mechanisms of this correlation remain unclear in most of the cancers [ 51 ]. It is generally accepted that the tumor can remodel microbial profiles by creating a more beneficial condition for the shifted microbiome [ 52–54 ].…”

Section: Discussionmentioning

confidence: 99%

The FnBPA from methicillin-resistant Staphylococcus aureus promoted development of oral squamous cell carcinoma

Kong

Wang

Shou

et al. 2022

Journal of Oral Microbiology

Self Cite

View full text Add to dashboard Cite

Background Oral squamous cell carcinoma (OSCC) is the most common tumor in the oral cavity. Methicillin-resistant Staphylococcus aureus (MRSA) were highly detected in OSCC patients; however, the interactions and mechanisms between drug-resistant bacteria (MRSA) and OSCC are not clear. Aim The aim of this study was to investigate the promotion of MRSA on the development of OSCC. Methods MRSA and MSSA (methicillin-susceptible) strains were employed to investigate the effect on the proliferation of OSCC in vitro and vivo . Results All of the MRSA strains significantly increased the proliferation of OSCC cells and MRSA arrested the cell cycles of OSCC cells in the S phase. MRSA activated the expression of TLR-4, NF-κB and c-fos in OSCC cells. MRSA also promoted the development of squamous cell carcinoma in vivo. The virulence factor fnbpA gene was significantly upregulated in all MRSA strains. By neutralizing FnBPA, the promotions of MRSA on OSCC cell proliferation and development of squamous cell carcinoma were significantly decreased. Meanwhile, the activation of c-fos and NF-κB by MRSA was also significantly decreased by FnBPA antibody. Conclusion MRSA promoted development of OSCC, and the FnBPA protein was the critical virulence factor. Targeting virulence factors is a new method to block the interaction between a drug-resistant pathogen and development of tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

The FnBPA from methicillin-resistant Staphylococcus aureus promoted development of oral squamous cell carcinoma

Kong

Wang

Shou

et al. 2022

Journal of Oral Microbiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…It has been established that tumor patients have distinct microbiota compared with healthy subjects ( 165 , 166 ). In addition, compared to patients that did not respond to immunotherapy, a unique intestinal microbiome was found in cancer patients that did respond to immunotherapy ( 167 ). Increasing evidence indicates that transplanting the gut microbiome of immunotherapy responders can activate immune cells and make immunotherapy nonresponders respond to immunotherapy ( 168 – 171 ).…”

Section: The Potential Role Of Certain Gut Microbiota As the Predicti...mentioning

confidence: 99%

Predictive biomarkers of colon cancer immunotherapy: Present and future

Hou

Zhu

2022

Front. Immunol.

View full text Add to dashboard Cite

Immunotherapy has revolutionized colon cancer treatment. Immune checkpoint inhibitors (ICIs) have shown clinical benefits for colon cancer patients, especially those with high microsatellite instability (MSI-H). In 2020, the US Food and Drug Administration (FDA)-approved ICI pembrolizumab as the first-line treatment for metastatic MSI-H colon cancer patients. Additionally, neoadjuvant immunotherapy has presented efficacy in treating early-stage colon cancer patients. Although MSI has been thought of as an effective predictive biomarker for colon cancer immunotherapy, only a small proportion of colon cancer patients were MSI-H, and certain colon cancer patients with MSI-H presented intrinsic or acquired resistance to immunotherapy. Thus, further search for predictive biomarkers to stratify patients is meaningful in colon cancer immunotherapy. Except for MSI, other biomarkers, such as PD-L1 expression level, tumor mutation burden (TMB), tumor-infiltrating lymphocytes (TILs), certain gut microbiota, ctDNA, and circulating immune cells were also proposed to be correlated with patient survival and ICI efficacy in some colon cancer clinical studies. Moreover, developing new diagnostic techniques helps identify accurate predictive biomarkers for colon cancer immunotherapy. In this review, we outline the reported predictive biomarkers in colon cancer immunotherapy and further discuss the prospects of technological changes for biomarker development in colon cancer immunotherapy.

show abstract

“…In addition, microbial dysbiosis is associated with tumor progression, clonal evolution and spreading to distant sites [102]. If malignant cells can model the microbiome [103], it has been also reported that distinct "dysbiotic signatures" [5] can act directly on tumor cells and indirectly through the suppression of immune response. Some experimental evidence documented the associations between Mycoplasma pn.…”

Section: How Where and When To Analyze Nsclc-related Microbiotamentioning

confidence: 99%

Pragmatic Expectancy on Microbiota and Non-Small Cell Lung Cancer: A Narrative Review

Stella

Scialò

Bortolotto

et al. 2022

Cancers

View full text Add to dashboard Cite

It is well known that lung cancer relies on a number of genes aberrantly expressed because of somatic lesions. Indeed, the lungs, based on their anatomical features, are organs at a high risk of development of extremely heterogeneous tumors due to the exposure to several environmental toxic agents. In this context, the microbiome identifies the whole assemblage of microorganisms present in the lungs, as well as in distant organs, together with their structural elements and metabolites, which actively interact with normal and transformed cells. A relevant amount of data suggest that the microbiota plays a role not only in cancer disease predisposition and risk but also in its initiation and progression, with an impact on patients’ prognosis. Here, we discuss the mechanistic insights of the complex interaction between lung cancer and microbiota as a relevant component of the microenvironment, mainly focusing on novel diagnostic and therapeutic objectives.

show abstract

The Interaction Between the Microbiome and Tumors

Cited by 16 publications

References 140 publications

The FnBPA from methicillin-resistant Staphylococcus aureus promoted development of oral squamous cell carcinoma

The FnBPA from methicillin-resistant Staphylococcus aureus promoted development of oral squamous cell carcinoma

Predictive biomarkers of colon cancer immunotherapy: Present and future

Pragmatic Expectancy on Microbiota and Non-Small Cell Lung Cancer: A Narrative Review

Contact Info

Product

Resources

About